Obesity epidemic: Overview, pathophysiology, and the intensive care unit conundrum

Journal of Parenteral and Enteral Nutrition

Volumn 35, Issue 5 SUPPL., 2011, Pages

  Hurt, Ryan T ^a,b   Frazier, Thomas H ^c   McClave, Stephen A ^c   Kaplan, Lee M ^d,e  

^a MAYO CLINIC   (United States)

^b Department of Medicine ^*  (United States)

^c University of Louisville School of Medicine   (United States)

^d HARVARD UNIVERSITY   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Body mass index; Critical care; Enteral nutrition; Metabolic syndrome; Obesity

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 6; LEPTIN; LEPTIN RECEPTOR; MELANOCORTIN 4 RECEPTOR; PROOPIOMELANOCORTIN; TUMOR NECROSIS FACTOR ALPHA;

ALLELE; APPETITE; BODY FAT DISTRIBUTION; BODY MASS; COMORBIDITY; ENERGY EXPENDITURE; EPIDEMIC; ETHNIC DIFFERENCE; FOOD INTAKE; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC SUSCEPTIBILITY; GENOTYPE ENVIRONMENT INTERACTION; INTENSIVE CARE UNIT; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; MULTIPLE ORGAN FAILURE; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTECTION; REVIEW; WEIGHT GAIN; ARTICLE; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CRITICAL ILLNESS; DIABETES MELLITUS; ENVIRONMENT; GENETIC PREDISPOSITION; HUMAN; LIFESTYLE; LIVER DISEASE; MOTOR ACTIVITY; NEOPLASM; RISK FACTOR; UNITED STATES;

CARDIOVASCULAR DISEASES; CRITICAL ILLNESS; DIABETES MELLITUS; ENERGY INTAKE; ENVIRONMENT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTENSIVE CARE UNITS; LIFE STYLE; LIVER DISEASES; MOTOR ACTIVITY; NEOPLASMS; OBESITY; RISK FACTORS; UNITED STATES; WEIGHT GAIN;

EID: 80053429500     PISSN: 01486071     EISSN: None     Source Type: Journal    
DOI: 10.1177/0148607111415110     Document Type: Review

References (80)

1. Ogden CL, Carroll MD, Flegal KM. Epidemiologic trends in overweight and obesity. Endocrinol Metab Clin North Am. 2003;32(4):741-760, vii.
2. Ogden CL, Yanovski SZ, Carroll MD, Flegal KM. The epidemiology of obesity. Gastroenterology. 2007;132(6):2087-2102.
3. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer- and service-specific estimates. Health Aff (Millwood). 2009;28(5):w822-w831.
4. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625-1638.
5. Smith SM, Gately P, Rudolf M. Can we recognise obesity clinically? Arch Dis Child. 2008;93(12):1065-1066.
6. Caccamese SM, Kolodner K, Wright SM. Comparing patient and physician perception of weight status with body mass index. Am J Med. 2002;112(8):662-666.
7. Bardia A, Holtan SG, Slezak JM, Thompson WG. Diagnosis of obesity by primary care physicians and impact on obesity management. Mayo Clin Proc. 2007;82(8):927-932.
8. Kuczmarski RJ, Flegal KM. Criteria for definition of overweight in transition: background and recommendations for the United States. Am J Clin Nutr. 2000;72(5):1074-1081.
9. Ogden CL, Carroll MD, McDowell MA, Flegal KM. Obesity among adults in the United States-no statistically significant chance since 2003-2004. NCHS Data Brief. 2007;(1):1-8.
10. Ogden CL, Flegal KM, Carroll MD, Johnson CL. Prevalence and trends in overweight among US children and adolescents, 1999-2000. JAMA. 2002;288(14):1728-1732.
11. Obesity prevalence among low-income, preschool-aged children- United States, 1998-2008. MMWR Morb Mortal Wkly Rep. 2009;58(28):769-773.
12. Fawcett KA, Barroso I. The genetics of obesity: FTO leads the way. Trends Genet. 2010;26(6):266-274.
13. Choi JW, Wang X, Joo JI, et al. Plasma proteome analysis in dietinduced obesity-prone and obesity-resistant rats. Proteomics. 2010;10(24):4386-4400.
14. Ogden CL, Carroll MD, Flegal KM. High body mass index for age among US children and adolescents, 2003-2006. JAMA. 2008;299(20):2401-2405.
15. Rosenbloom AL, Joe JR, Young RS, Winter WE. Emerging epidemic of type 2 diabetes in youth. Diabetes Care. 1999;22(2):345-354.
16. Ogden CL, Troiano RP, Briefel RR, Kuczmarski RJ, Flegal KM, Johnson CL. Prevalence of overweight among preschool children in the United States, 1971 through 1994. Pediatrics. 1997;99(4):E1.
17. Flegal KM, Ogden CL, Carroll MD. Prevalence and trends in overweight in Mexican-American adults and children. Nutr Rev. 2004;62(7, pt 2):S144-S148.
18. Flegal KM, Ogden CL, Wei R, Kuczmarski RL, Johnson CL. Prevalence of overweight in US children: comparison of US growth charts from the Centers for Disease Control and Prevention with other reference values for body mass index. Am J Clin Nutr. 2001;73(6):1086-1093.
19. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367(9524):1747-1757.
20. James PT. Obesity: the worldwide epidemic. Clin Dermatol. 2004;22(4):276-280.
21. Goh VH, Tain CF, Tong TY, Mok HP, Wong MT. Are BMI and other anthropometric measures appropriate as indices for obesity? A study in an Asian population. J Lipid Res. 2004;45(10): 1892-1898.
22. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403): 157-163.
23. Stevens J, Nowicki EM. Body mass index and mortality in Asian populations: implications for obesity cut-points. Nutr Rev. 2003;61(3):104-107.
24. Woods SC, D'Alessio DA. Central control of body weight and appetite. J Clin Endocrinol Metab. 2008;93(11)(suppl 1):S37-S50.
25. Woods SC, Seeley RJ, Cota D. Regulation of food intake through hypothalamic signaling networks involving mTOR. Annu Rev Nutr. 2008;28:295-311.
26. Bouchard C. Gene-environment interactions in the etiology of obesity: defining the fundamentals. Obesity (Silver Spring). 2008; 16(suppl 3):S5-S10.
27. Agurs-Collins T, Bouchard C. Gene-nutrition and gene-physical activity interactions in the etiology of obesity: introduction. Obesity (Silver Spring). 2008;16(suppl 3):S2-S4.
28. Chung WK, Leibel RL. Considerations regarding the genetics of obesity. Obesity (Silver Spring). 2008;16(suppl 3):S33-S39.
29. Farooqi S, O'Rahilly S. Genetics of obesity in humans. Endocr Rev. 2006;27(7):710-718.
30. Farooqi IS, Jebb SA, Langmack G, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999;341(12):879-884.
31. Hinney A, Vogel CI, Hebebrand J. From monogenic to polygenic obesity: recent advances. Eur Child Adolesc Psychiatry. 2010;19(3): 297-310.
32. Hinney A, Hebebrand J. Polygenic obesity in humans. Obes Facts. 2008;1(1):35-42.
33. Speliotes EK, Willer CJ, Berndt SI, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet. 2010;42(11):937-948.
34. Cauchi S, Stutzmann F, Cavalcanti-Proenca C, et al. Combined effects of MC4R and FTO common genetic variants on obesity in European general populations. J Mol Med. 2009;87(5):537-546.
35. Stutzmann F, Cauchi S, Durand E, et al. Common genetic variation near MC4R is associated with eating behaviour patterns in European populations. Int J Obes (Lond). 2009;33(3):373-378.
36. Bray GA, Nielsen SJ, Popkin BM. Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. Am J Clin Nutr. 2004;79(4):537-543.
37. Bantle JP. Dietary fructose and metabolic syndrome and diabetes. J Nutr. 2009;139(6):1263S-1268S.
38. Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ. 2008;336 (7639):309-312.
39. Bantle JP, Raatz SK, Thomas W, Georgopoulos A. Effects of dietary fructose on plasma lipids in healthy subjects. Am J Clin Nutr. 2000;72(5):1128-1134.
40. Vos MB, Kimmons JE, Gillespie C, Welsh J, Blanck HM. Dietary fructose consumption among US children and adults: the Third National Health and Nutrition Examination Survey. Medscape J Med. 2008;10(7):160.
41. Stender S, Astrup A, Dyerberg J. Ruminant and industrially produced trans fatty acids: health aspects. Food Nutr Res. 2008;52.
42. Stender S, Dyerberg J. Influence of trans fatty acids on health. Ann Nutr Metab. 2004;48(2):61-66.
43. Stender S, Dyerberg J, Astrup A. High levels of industrially produced trans fat in popular fast foods. N Engl J Med. 2006;354(15):1650-1652.
44. Stender S, Dyerberg J, Astrup A. Fast food: unfriendly and unhealthy. Int J Obes (Lond). 2007;31(6):887-890.
45. Dansinger M. Ban trans fats in 2007. MedGenMed. 2006;8(4):58.
46. Mozaffarian D, Abdollahi M, Campos H, Houshiarrad A, Willett WC. Consumption of trans fats and estimated effects on coronary heart disease in Iran. Eur J Clin Nutr. 2007;61(8):1004-1010.
47. Mozaffarian D, Willett WC. Trans fatty acids and cardiovascular risk: a unique cardiometabolic imprint? Curr Atheroscler Rep. 2007;9(6):486-493.
48. Willett WC, Stampfer MJ, Manson JE, et al. Intake of trans fatty acids and risk of coronary heart disease among women. Lancet. 1993;341(8845):581-585.
49. Pietinen P, Ascherio A, Korhonen P, et al. Intake of fatty acids and risk of coronary heart disease in a cohort of Finnish men. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Am J Epidemiol. 1997;145(10):876-887.
50. Williamson DF, Madans J, Anda RF, Kleinman JC, Kahn HS, Byers T. Recreational physical activity and ten-year weight change in a US national cohort. Int J Obes Relat Metab Disord. 1993;17(5):279-286.
51. Ravussin E, Lillioja S, Knowler WC, et al. Reduced rate of energy expenditure as a risk factor for body-weight gain. N Engl J Med. 1988;318(8):467-472.
52. Chandra R, Liddle RA. Cholecystokinin. Curr Opin Endocrinol Diabetes Obes. 2007;14(1):63-67.
53. Lorenz DN, Goldman SA. Vagal mediation of the cholecystokinin satiety effect in rats. Physiol Behav. 1982;29(4):599-604.
54. Edwards GL, Ladenheim EE, Ritter RC. Dorsomedial hindbrain participation in cholecystokinin-induced satiety. Am J Physiol. 1986;251(5, pt 2):R971-R977.
55. Wiedmer P, Nogueiras R, Broglio F, D'Alessio D, Tschop MH. Ghrelin, obesity and diabetes. Nat Clin Pract Endocrinol Metab. 2007;3(10):705-712.
56. Asakawa A, Inui A, Kaga T, et al. Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology. 2001;120(2):337-345.
57. Kreitschmann-Andermahr I, Suarez P, Jennings R, Evers N, Brabant G. GH/IGF-I regulation in obesity-mechanisms and practical consequences in children and adults. Horm Res Paediatr. 2010;73(3):153-160.
58. Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346(21):1623-1630.
59. Hanusch-Enserer U, Cauza E, Brabant G, et al. Plasma ghrelin in obesity before and after weight loss after laparoscopical adjustable gastric banding. J Clin Endocrinol Metab. 2004;89(7):3352-3358.
60. Foster-Schubert KE, McTiernan A, Frayo RS, et al. Human plasma ghrelin levels increase during a one-year exercise program. J Clin Endocrinol Metab. 2005;90(2):820-825.
61. Dube PE, Brubaker PL. Nutrient, neural and endocrine control of glucagon-like peptide secretion. Horm Metab Res. 2004;36(11- 12):755-760.
62. Kinzig KP, D'Alessio DA, Seeley RJ. The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. J Neurosci. 2002;22(23):10470-10476.
63. Larsen PJ, Tang-Christensen M, Jessop DS. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology. 1997;138(10):4445-4455.
64. Larsen PJ, Tang-Christensen M, Holst JJ, Orskov C. Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience. 1997;77(1):257-270.
65. Gutzwiller JP, Drewe J, Goke B, et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol. 1999;276(5, pt 2):R1541-R1544.
66. McMahon LR, Wellman PJ. Decreased intake of a liquid diet in nonfood-deprived rats following intra-PVN injections of GLP-1 (7-36) amide. Pharmacol Biochem Behav. 1997;58(3):673-677.
67. Naslund E, Bogefors J, Skogar S, et al. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol. 1999;277(3, pt 2):R910-R916.
68. Mafong DD, Henry RR. Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction. Curr Atheroscler Rep. 2008;10(1):55-60.
69. Adams KF, Schatzkin A, Harris TB, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med. 2006;355(8):763-778.
70. Pischon T, Boeing H, Hoffmann K, et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med. 2008;359(20): 2105-2120.
71. McTigue K, Larson JC, Valoski A, et al. Mortality and cardiac and vascular outcomes in extremely obese women. JAMA. 2006;296(1): 79-86.
72. Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373(9669):1083-1096.
73. Field AE, Coakley EH, Must A, et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med. 2001;161(13):1581-1586.
74. Brodsky JB, Lemmens HJ, Brock-Utne JG, Vierra M, Saidman LJ. Morbid obesity and tracheal intubation. Anesth Analg. 2002;94(3): 732-736.
75. Ladosky W, Botelho MA, Albuquerque JP Jr. Chest mechanics in morbidly obese non-hypoventilated patients. Respir Med. 2001; 95(4):281-286.
76. Hogue CW Jr, Stearns JD, Colantuoni E, et al. The impact of obesity on outcomes after critical illness: a meta-analysis. Intensive Care Med. 2009;35(7):1152-1170.
77. Akinnusi ME, Pineda LA, El Solh AA. Effect of obesity on intensive care morbidity and mortality: a meta-analysis. Crit Care Med. 2008;36(1):151-158.
78. Oliveros H, Villamor E. Obesity and mortality in critically ill adults: a systematic review and meta-analysis. Obesity (Silver Spring). 2008;16(3):515-521.
79. Cave MC, Hurt RT, Frazier TH, et al. Obesity, inflammation, and the potential application of pharmaconutrition. Nutr Clin Pract. 2008;23(1):16-34.
80. Matheson PJ, Hurt RT, Franklin GA, McClain CJ, Garrison RN. Obesity-induced hepatic hypoperfusion primes for hepatic dysfunction after resuscitated hemorrhagic shock. Surgery. 2009; 146(4):739-747; discussion 747-748.